nach oben

18.05.2024 | Original Article

Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study

verfasst von: Yuting Gao, Tianyi Zhao, Na Lv, Shixuan Liu, Tao Yuan, Yong Fu, Weigang Zhao, Baoli Zhu

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

Background

The influence of the microbiota on hypoglycemic agents is becoming more apparent. The effects of metformin, a primary anti-diabetes drug, on gut microbiota are still not fully understood.

Research design and methods

This prospective cohort study aims to investigate the longitudinal effects of metformin on the gut microbiota of 25 treatment-naïve diabetes patients, each receiving a daily dose of 1500 mg. Microbiota compositions were analyzed at baseline, and at 1, 3, and 6 months of medication using 16S rRNA gene sequencing.

Results

Prior to the 3-month period of metformin treatment, significant improvements were noted in body mass index (BMI) and glycemic-related parameters, such as fasting blood glucose (FPG) and hemoglobin A1c (HbA1c), alongside homeostasis model assessment indices of insulin resistance (HOMA-IR). At the 3-month mark of medication, a significant reduction in the α-diversity of the gut microbiota was noted, while β-diversity exhibited no marked variances throughout the treatment duration. The Firmicutes to Bacteroidetes ratio. markedly decreased. Metformin treatment consistently increased Escherichia-Shigella and decreased Romboutsia, while Pseudomonas decreased at 3 months. Fuzzy c-means clustering identified three longitudinal trajectory clusters for microbial fluctuations: (i) genera temporarily changing, (ii) genera continuing to decrease (Bacteroides), and (iii) genera continuing to increase(Lachnospiraceae ND3007 group, [Eubacterium] xylanophilum group, Romboutsia, Faecalibacterium and Ruminococcaceae UCG-014). The correlation matrix revealed associations between specific fecal taxa and metformin-related clinical parameters HbA1c, FPG, Uric Acid (UA), high-density lipoproteincholesterol (HDL-C), alanine aminotransferase (ALT), hypersensitive C-reactive protein (hs-CRP), triglyceride (TG) (P < 0.05). Metacyc database showed that metformin significantly altered 17 functional pathways. Amino acid metabolism pathways such as isoleucine biosynthesis predominated in the post-treatment group.

Conclusions

Metformin’s role in glucose metabolism regulation may primarily involve specific alterations in certain gut microbial species rather than an overall increase in microbial species diversity. This may suggest gut microbiota targets in future studies on metabolic abnormalities caused by metformin.

Nur mit Berechtigung zugänglich

Collaborators GBDD, Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397), 203–234 (2023). https://doi.org/10.1016/S0140-6736(23)01301-6CrossRef

U. Galicia-Garcia, A. Benito-Vicente, S. Jebari, A. Larrea-Sebal, H. Siddiqi, K.B. Uribe et al. Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 21(17), 6275 (2020). https://doi.org/10.3390/ijms21176275CrossRefPubMedPubMedCentral

H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova, B.B. Duncan et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022). https://doi.org/10.1016/j.diabres.2021.109119CrossRefPubMed

H. Tilg, A.R. Moschen, Microbiota and diabetes: an evolving relationship. Gut 63(9), 1513–1521 (2014). https://doi.org/10.1136/gutjnl-2014-306928CrossRefPubMed

A.L. Cunningham, J.W. Stephens, D.A. Harris, Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut. Pathog. 13(1), 50 (2021). https://doi.org/10.1186/s13099-021-00446-0CrossRefPubMedPubMedCentral

R. Li, F. Shokri, A.L. Rincon, F. Rivadeneira, C. Medina-Gomez, F. Ahmadizar, Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review. Genes. 14(8) (2023) https://doi.org/10.3390/genes14081572

M. Foretz, B. Guigas, B. Viollet, Metformin: update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19(8), 460–476 (2023). https://doi.org/10.1038/s41574-023-00833-4CrossRefPubMed

L.J. McCreight, C.J. Bailey, E.R. Pearson, Metformin and the gastrointestinal tract. Diabetologia 59(3), 426–435 (2016). https://doi.org/10.1007/s00125-015-3844-9CrossRefPubMedPubMedCentral

C.J. Bailey, C. Wilcock, J.H. Scarpello, Metformin and the intestine. Diabetologia 51(8), 1552–1553 (2008). https://doi.org/10.1007/s00125-008-1053-5CrossRefPubMed

10.

E. Bonora, M. Cigolini, O. Bosello, C. Zancanaro, L. Capretti, I. Zavaroni et al. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr. Med. Res. Opin. 9(1), 47–51 (1984). https://doi.org/10.1185/03007998409109558CrossRefPubMed

11.

J.B. Buse, R.A. DeFronzo, J. Rosenstock, T. Kim, C. Burns, S. Skare et al. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care 39(2), 198–205 (2016). https://doi.org/10.2337/dc15-0488CrossRefPubMed

12.

N.R. Shin, J.C. Lee, H.Y. Lee, M.S. Kim, T.W. Whon, M.S. Lee et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63(5), 727–735 (2014). https://doi.org/10.1136/gutjnl-2012-303839CrossRefPubMed

13.

P. Pavlo, I. Kamyshna, A. Kamyshnyi, Effects of metformin on the gut microbiota: A systematic review. Mol. Metab. 77, 101805 (2023). https://doi.org/10.1016/j.molmet.2023.101805CrossRef

14.

N.T. Mueller, M.K. Differding, M. Zhang, N.M. Maruthur, S.P. Juraschek, E.R. Miller 3rd et al. Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. Diabetes Care 44(7), 1462–1471 (2021). https://doi.org/10.2337/dc20-2257CrossRefPubMedPubMedCentral

15.

J. de la Cuesta-Zuluaga, N.T. Mueller, V. Corrales-Agudelo, E.P. Velasquez-Mejia, J.A. Carmona, J.M. Abad et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care 40(1), 54–62 (2017). https://doi.org/10.2337/dc16-1324CrossRefPubMed

16.

K. Forslund, F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528(7581), 262–266 (2015). https://doi.org/10.1038/nature15766CrossRefPubMedPubMedCentral

17.

F. Zhang, M. Wang, J. Yang, Q. Xu, C. Liang, B. Chen et al. Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine 66(3), 485–493 (2019). https://doi.org/10.1007/s12020-019-02041-5CrossRefPubMed

18.

I. Elbere, I. Silamikelis, I.I. Dindune, I. Kalnina, M. Ustinova, L. Zaharenko et al. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. PLoS One 15(10), e0241338 (2020). https://doi.org/10.1371/journal.pone.0241338CrossRefPubMedPubMedCentral

19.

L. Sun, C. Xie, G. Wang, Y. Wu, Q. Wu, X. Wang et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24(12), 1919–1929 (2018). https://doi.org/10.1038/s41591-018-0222-4CrossRefPubMedPubMedCentral

20.

H. Nakajima, F. Takewaki, Y. Hashimoto, S. Kajiyama, S. Majima, H. Okada et al. The Effects of Metformin on the Gut Microbiota of Patients with Type 2 Diabetes: A Two-Center, Quasi-Experimental Study. Life 10(9), 195 (2020). https://doi.org/10.3390/life10090195CrossRefPubMedPubMedCentral

21.

A. Napolitano, S. Miller, A.W. Nicholls, D. Baker, S. Van Horn, E. Thomas et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 9(7), e100778 (2014). https://doi.org/10.1371/journal.pone.0100778CrossRefPubMedPubMedCentral

22.

T. Magoc, S.L. Salzberg, FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27(21), 2957–2963 (2011). https://doi.org/10.1093/bioinformatics/btr507CrossRefPubMedPubMedCentral

23.

C.A. Dennison, A.J. Eslinger, R.A. Reimer, Preconception Prebiotic and Sitagliptin Treatment in Obese Rats Affects Pregnancy Outcomes and Offspring Microbiota, Adiposity, and Glycemia. Front. Endocrinol. 8, 301 (2017). https://doi.org/10.3389/fendo.2017.00301CrossRef

24.

N. Segata, J. Izard, L. Waldron, D. Gevers, L. Miropolsky, W.S. Garrett et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12(6), R60 (2011). https://doi.org/10.1186/gb-2011-12-6-r60CrossRefPubMedPubMedCentral

25.

M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(12), 550 (2014). https://doi.org/10.1186/s13059-014-0550-8CrossRefPubMedPubMedCentral

26.

R.L. Cannon, J.V. Dave, J.C. Bezdek, Efficient Implementation of the Fuzzy c-Means Clustering Algorithms. IEEE Trans. Pattern Anal. Mach. Intell. 8(2), 248–255 (1986). https://doi.org/10.1109/tpami.1986.4767778CrossRefPubMed

27.

G.M. Douglas, V.J. Maffei, J.R. Zaneveld, S.N. Yurgel, J.R. Brown, C.M. Taylor et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38(6), 685–688 (2020). https://doi.org/10.1038/s41587-020-0548-6CrossRefPubMedPubMedCentral

28.

A. Koh, F. De Vadder, P. Kovatcheva-Datchary, F. Backhed, From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 165(6), 1332–1345 (2016). https://doi.org/10.1016/j.cell.2016.05.041CrossRefPubMed

29.

S.Y. Park, A. Ufondu, K. Lee, A. Jayaraman, Emerging computational tools and models for studying gut microbiota composition and function. Curr. Opin. Biotechnol. 66, 301–311 (2020). https://doi.org/10.1016/j.copbio.2020.10.005CrossRefPubMedPubMedCentral

30.

I. Elbere, I. Kalnina, I. Silamikelis, I. Konrade, L. Zaharenko, K. Sekace et al. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS One 13(9), e0204317 (2018). https://doi.org/10.1371/journal.pone.0204317CrossRefPubMedPubMedCentral

31.

S. Mrozinska, P. Radkowski, T. Gosiewski, M. Szopa, M. Bulanda, A.H. Ludwig-Galezowska et al. Qualitative Parameters of the Colonic Flora in Patients with HNF1A-MODY Are Different from Those Observed in Type 2 Diabetes Mellitus. J. Diabetes Res. 2016, 3876764 (2016). https://doi.org/10.1155/2016/3876764CrossRefPubMedPubMedCentral

32.

A. Chavez-Carbajal, M.L. Pizano-Zarate, F. Hernandez-Quiroz, G.F. Ortiz-Luna, R.M. Morales-Hernandez, A. De Sales-Millan et al. Characterization of the Gut Microbiota of Individuals at Different T2D Stages Reveals a Complex Relationship with the Host. Microorganisms 8(1), 94 (2020). https://doi.org/10.3390/microorganisms8010094CrossRefPubMedPubMedCentral

33.

E. Sepp, H. Kolk, K. Loivukene, M. Mikelsaar Higher blood glucose level associated with body mass index and gut microbiota in elderly people. Microb. Ecol. Health Dis. 25 (2014). https://doi.org/10.3402/mehd.v25.22857

34.

P.M. Ryan, E. Patterson, I. Carafa, R. Mandal, D.S. Wishart, T.G. Dinan et al. Metformin and Dipeptidyl Peptidase-4 Inhibitor Differentially Modulate the Intestinal Microbiota and Plasma Metabolome of Metabolically Dysfunctional Mice. Can. J. Diabetes 44(2), 146–55.e2 (2020). https://doi.org/10.1016/j.jcjd.2019.05.008CrossRefPubMed

35.

N. Larsen, F.K. Vogensen, F.W. van den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2), e9085 (2010). https://doi.org/10.1371/journal.pone.0009085CrossRefPubMedPubMedCentral

36.

H.S. Ejtahed, R.Y. Tito, S.D. Siadat, S. Hasani-Ranjbar, Z. Hoseini-Tavassol, L. Rymenans et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. Eur. J. Endocrinol. 180(3), 165–176 (2019). https://doi.org/10.1530/EJE-18-0826CrossRefPubMed

37.

X. Niu, P. Lu, L. Huang, Y. Sun, M. Jin, J. Liu, et al. The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes. Int. Microbiol. (2023). https://doi.org/10.1007/s10123-023-00380-y

38.

L. Crovesy, D. Masterson, E.L. Rosado, Profile of the gut microbiota of adults with obesity: a systematic review. Eur. J. Clin. Nutr. 74(9), 1251–1262 (2020). https://doi.org/10.1038/s41430-020-0607-6CrossRefPubMed

39.

C.K. Chakraborti, New-found link between microbiota and obesity. World J. Gastrointest. Pathophysiol. 6(4), 110–119 (2015). https://doi.org/10.4291/wjgp.v6.i4.110CrossRefPubMedPubMedCentral

40.

T. Tavella, S. Rampelli, G. Guidarelli, A. Bazzocchi, C. Gasperini, E. Pujos-Guillot et al. Elevated gut microbiome abundance of Christensenellaceae, Porphyromonadaceae and Rikenellaceae is associated with reduced visceral adipose tissue and healthier metabolic profile in Italian elderly. Gut Microbes 13(1), 1–19 (2021). https://doi.org/10.1080/19490976.2021.1880221CrossRefPubMed

41.

J.L. Kubinak, C. Petersen, W.Z. Stephens, R. Soto, E. Bake, R.M. O’Connell et al. MyD88 signaling in T cells directs IgA-mediated control of the microbiota to promote health. Cell Host Microbe 17(2), 153–163 (2015). https://doi.org/10.1016/j.chom.2014.12.009CrossRefPubMedPubMedCentral

42.

Q. Zeng, D. Li, Y. He, Y. Li, Z. Yang, X. Zhao et al. Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities. Sci. Rep. 9(1), 13424 (2019). https://doi.org/10.1038/s41598-019-49462-wCrossRefPubMedPubMedCentral

43.

P. Guilloteau, L. Martin, V. Eeckhaut, R. Ducatelle, R. Zabielski, F. Van Immerseel, From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr. Res. Rev. 23(2), 366–384 (2010). https://doi.org/10.1017/S0954422410000247CrossRefPubMed

44.

S. Wu, C. Sun, Y. Li, T. Wang, L. Jia, S. Lai et al. GMrepo: a database of curated and consistently annotated human gut metagenomes. Nucleic Acids Res. 48(D1), D545–D553 (2020). https://doi.org/10.1093/nar/gkz764CrossRefPubMed

45.

M. Tong, X. Li, L. Wegener Parfrey, B. Roth, A. Ippoliti, B. Wei et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One 8(11), e80702 (2013). https://doi.org/10.1371/journal.pone.0080702CrossRefPubMedPubMedCentral

46.

P. Wang, J. Gao, W. Ke, J. Wang, D. Li, R. Liu et al. Resveratrol reduces obesity in high-fat diet-fed mice via modulating the composition and metabolic function of the gut microbiota. Free Radic. Biol. Med. 156, 83–98 (2020). https://doi.org/10.1016/j.freeradbiomed.2020.04.013CrossRefPubMed

47.

Q. Luo, D. Cheng, C. Huang, Y. Li, C. Lao, Y. Xia et al. Improvement of Colonic Immune Function with Soy Isoflavones in High-Fat Diet-Induced Obese Rats. Molecules 24(6), 1139 (2019). https://doi.org/10.3390/molecules24061139CrossRefPubMedPubMedCentral

48.

P. Fan, P. Liu, P. Song, X. Chen, X. Ma, Moderate Dietary Protein Restriction Alters the Composition of Gut Microbiota and Improves Ileal Barrier Function in Adult Pig Model. Sci. Rep. 7, 43412 (2017). https://doi.org/10.1038/srep43412CrossRefPubMedPubMedCentral

49.

W.Y. Yang, Y. Lee, H. Lu, C.H. Chou, C. Wang, Analysis of Gut Microbiota and the Effect of Lauric Acid Against Necrotic Enteritis in Clostridium Perfringens and Eimeria Side-by-Side Challenge Model. PloS One 14(5), e0205784 (2019). https://doi.org/10.1371/journal.pone.0205784CrossRefPubMedPubMedCentral

50.

H. Wu, E. Esteve, V. Tremaroli, M.T. Khan, R. Caesar, L. Manneras-Holm et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23(7), 850–858 (2017). https://doi.org/10.1038/nm.4345CrossRefPubMed

51.

Q. Zhang, X. Xiao, J. Zheng, M. Li, M. Yu, F. Ping et al. Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp. Biol. Med. 243(1), 34–44 (2018). https://doi.org/10.1177/1535370217743765CrossRef

52.

M. Million, E. Angelakis, M. Maraninchi, M. Henry, R. Giorgi, R. Valero et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int. J. Obes. 37(11), 1460–1466 (2013). https://doi.org/10.1038/ijo.2013.20CrossRef

53.

C. Pedersen, U.Z. Ijaz, E. Gallagher, F. Horton, R.J. Ellis, E. Jaiyeola et al. Fecal Enterobacteriales enrichment is associated with increased in vivo intestinal permeability in humans. Physiol. Rep. 6(7), e13649 (2018). https://doi.org/10.14814/phy2.13649CrossRefPubMedPubMedCentral

54.

Y. Que, M. Cao, J. He, Q. Zhang, Q. Chen, C. Yan et al. Gut Bacterial Characteristics of Patients With Type 2 Diabetes Mellitus and the Application Potential. Front. Immunol. 12, 722206 (2021). https://doi.org/10.3389/fimmu.2021.722206CrossRefPubMedPubMedCentral

Titel: Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study
verfasst von: Yuting Gao
Tianyi Zhao
Na Lv
Shixuan Liu
Tao Yuan
Yong Fu
Weigang Zhao
Baoli Zhu
Publikationsdatum: 18.05.2024
Verlag: Springer US
Erschienen in: Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-024-03828-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study

Abstract

Background

Research design and methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Research design and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin